Sage Journals: Discover world-class research

Abstract

The Qing-Re-Yi-Liu decoction (QRYLD) is a clinically effective prescription for treatment of breast cancer. Our preliminary studies found that QRYLD treatment interfered with the Warburg effect in breast cancer cells. However, its chemical components and molecular mechanisms have not been clarified. This study analyzed the bioactive components of QRYLD aqueous extracts by HPLC. The effects of QRYLD on the malignant behaviors of MCF-7 cells and potential mechanisms were analyzed by CCK-8, transwell invasion, wound-healing assays, flow cytometry, Western blot assays and transcriptomic analysis as well as in vivo mouse tumor model. QRYLD aqueous extracts contained several bioactive components. Transcriptomic analysis indicated that QRYLD treatment altered the expression of several genes involved in biological processes and signaling pathways, such as manganese superoxide dismutase (MnSOD). Functionally, QRYLD, similar to MnSOD silencing, inhibited the malignant behaviors of MCF-7 cells and enhanced their apoptosis, whereas MnSOD overexpression had the opposite effects. Moreover, QRYLD treatment inhibited the Warburg effect by limiting glucose uptake and lactic acid production, and decreasing the relative expression of glucose transporter-1, hypoxia-inducible factor 1α, c-Myc, hexokinase-2, phosphofructokinase 1, lactate dehydrogenase A, pyruvate kinase isozyme 2, MnSOD, calmodulin-dependent kinase II (CaMKII), and AMP-activated protein kinase (AMPK) in MCF-7 cells. Finally, treatment with QRYLD significantly inhibited the growth of xenografted MCF-7 tumors in mice and reduced the tumor expression of MnSOD, CaMKII, and AMPK. These data suggest that QRYLD may target MnSOD to attenuate the MnSOD/CaMKII/AMPK signaling, inhibiting the Warburg effect and malignant behaviors in breast cancer.

Keywords

QRYLD MnSOD malignant behaviors Warburg effect CaMKII/AMPK signaling

Introduction

Breast cancer is the most common malignant tumor in women globally. Currently, therapeutic strategies for breast cancer include surgical resection and neoadjuvant and postoperative therapies, such as chemotherapy, target therapy, radiotherapy, and immunotherapy. Traditional Chinese medicine (TCM) has been used to treat breast cancer.

In the theory of TCM, tumor development and progression are attributed to the accumulation of heat and toxin, and therapeutic strategies to clear heat and detoxify are important for the control of tumor growth. However, little is known on the therapeutic targets and pharmacological mechanisms underlying the anti-cancer activity of TCMs. Previous studies have shown that Scutellaria baicalensis and its bioactive ingredients have potent activities against the malignancy of breast cancer,¹ and treatment with the ethanolic extract of Andrographis paniculata inhibits the proliferation of human breast cancer MCF-7 cells in a dose-dependent manner.² Similarly, treatment with Coptidis Rhizoma limits the growth of 4T1 breast cancer in mice by inducing cell cycle arrest in G1 phase and suppressing DNA synthesis,³ whereas treatment with Radix Isatidis attenuates the malignant behaviors of SK-BR-1 and MDA-MB-231 cells in a time-dependent manner by inducing cell cycle G2/M arrest and apoptosis.⁴ Furthermore, treatment with Pulsatilla saponin inhibits the proliferation of MCF-7 cells in a dose-dependent manner.⁵ Although many TCMs have been used in clinical practice to treat breast cancer, their therapeutic efficacy remains limited. Hence, the identification of new and safe TCMs, particularly for those with potent heat-clearing and detoxifying activities, is urgently needed.

The Qing-Re-Yi-Liu decoction (QRYLD) is a clinically effective prescription for the treatment of breast cancer given its heat-clearing and detoxification activities. Our preliminary studies found that treatment with QRYLD inhibited the proliferation of MCF-7 cells, and this effect was associated with inhibition of the Warburg effect (aerobic glycolysis). However, its therapeutic target and the pharmacological mechanisms underlying the antitumor activity of QRYLD against the malignancy of MCF-7 breast tumors and the Warburg effect have not been explored.

Prvious studies have shown that the MnSOD/CaMKII/AMPK signaling is crucial for the Warburg effect, which is preferred by tumor cells.⁶ The MnSOD is a manganese-containing homotetramer in the mitochondrial matrix.⁷ MnSOD expression is up-regulated in breast cacner, and is associated with its aggrasiveness and worse prognosis.⁸ MnSOD overexpression promotes metastasis and drug resistance in breast cancer, but it also inhibits the proliferation of breast cancer cells by reducing ROS production and attenuating the PI3K/AKT and MAPK/ERK signaling.⁹ Furthermore, MnSOD can also activate CaMKII and AMPK to enhance glycolysis by enhancing its key enxyme expression in breast cancer cells.^10,11 Thus, MnSOD may act as a tumor suppressor or oncogenic factor. However, it is unclear whether QRYLD treatment could modulate the MnSOD/CaMKII/AMPK signlaing and subsequent the Warburg effect in breast cancer cells.

Materials and Methods

QRYLD

QRYLD is composed of Taraxacum officinale L., Iphigenia indica L., Forsythia suspensa L., Cortex Moutan, Hedyotis diffusa L., Lonicera japonica L., Prunella vulgaris L., and Lycii Cortex L. Further details about these components are presented in Table 1 (the plant names were verified at www.worldfloraonline.org). These medicinal herbs were obtained from the TCM Pharmacy of the First Affiliated Hospital of Xi’an Jiaotong University (Xi’an, Shaanxi, China) and identified by experts in the Pharmacy Department. QRYLD was soaked in 10 volumes of water and heated at 100 °C for 1 h. The decoction was collected, and the herbs were heated at 100 °C with another 10 volumes of water for 40 min for further decoction collection. The collected decoctions were mixed, filtered through a filter, concentrated, and dried using a spray dryer (Lemal, Changzhou, China). The dried QRYLD powder was dissolved in water, and the chemical components in the QRYLD aqueous extracts were identified by HPLC using an Agilent 1260 Infinity II HPLC system (Agilent Technologies, Santa Clara, CA, USA).

Table 1.

The Composition of QRYLD.

Family	Species	Chinese name	Dosage (g)	Part	Lot No.	Traditional effects	References
Asteraceae	Taraxacum officinale L.	Pugongying	30	Herba	210601	Anti-bacterial, antioxidant, anti-cancer, anti-rheumatic	^12–15
Colchicaceae	Iphigenia indica L.	Shancigu	30	Caulis	210501	Anti-cancer, anti-inflammatory, pain-relieving, anti-hypertensive, cough-relieving, asthma-relieving	^16–18
Oleaceae	Forsythia suspensa L.	Lianqiao	15	Fructus	210801	Anti-bacterial, anti-pyretic, anti-emetic, anti-inflammatory, diuretic, hepatoprotective, cardiotonic, diuretic, anti-hypertensive	^19–22
Paeoniaceae	Cortex Moutan L.	Mudanpi	15	Radix bark	210701	Anti-bacterial, anti-inflammatory, anti-allergic, hepatoprotective, hypoglycemic, anti-cancer	^23–26
Rubiaceae	Hedyotis diffusa L.	Baihuasheshecao	30	Herba	210601	Anti-inflammatory, anti-cancer, analgesic, hepatoprotective, gallbladder-protecting	^27–30
Caprifoliaceae	Lonicera japonica L.	Jinyinhua	15	Flos	210601	Anti-inflammatory, anti-pyretic, anti-endotoxin, hypolipidemic	^31–34
Lamiaceae	Prunella vulgaris L.	Xiakucao	15	Fructus	210801	Anti-hypertensive, hypoglycemic, anti-bacterial, anti-inflammatory, anti-allergic, anti-viral	^35–38
Canellaceae	Lycii Cortex L.	Digupi	15	Radix bark	210501	Anti-pyretic, anti-hypertensive, hypoglycemic, anti-cancer, lipid-lowering	^39–41

The plant names have been checked at http://www.theplantlist.org and www.worldfloraonline.org.

Preparation of QRYLD-Supplemented Serum

BALB/c mice at 3–5 weeks of age were obtained from the Laboratory Animal Center, Xi’an Jiaotong University Health Science Center. The mice were randomized and treated with the control physiological saline or 0.3 ml of QRYLD in physiological saline at a low (LD, 5.6875 g·kg⁻¹·day⁻¹), medium (MD, 11.375 g·kg⁻¹·day⁻¹) or high dose (HD, 22.75 g·kg⁻¹·day⁻¹) by gavage daily for 7 consecutive days. The daily medium dose of QRYLD for mice was calculated according to that individual adults with an average of body surface area of 1.7 m² take about 400 ml of QRYLD per day and then converted into mouse dose, based on the ratio of body surface area of humans to mice. Two hours after the last gavage, their blood samples were collected and prepared for serum samples. After being heated at 56 °C for 30 min, the serum samples were filtered through a 0.45-µm filter and used as the QRYLD-supplemented sera for cell culture. RPMI-1640 medium (Solarbio, Beijing, China) containing 10% QRYLD-supplemented serum was prepared.

Cell Culture

Human breast cancer MCF-7 cells were obtained from Shanghai Institute of Cell Biology (Shanghai, China) and cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C in a 5% CO₂ incubator.

Transfection and Transduction

293 T cells were transfected with plasmids for lentivirus packaging and MnSOD expression or control GFP expression using Lipofectamine 3000 to generate the lentivirus virions carrying cDNA for the expression of MnSOD (Lent-MnSOD) and control GFP (Lent-GFP), respectively. Similarly, HEK293 cells were transfected with adenovirus packaging plasmids and plasmids for the expression of MnSOD-specific shRNA or control shRNA to generate Ad-sh-MnSOD and control Ad-sh virions, respectively. These lentivirus and adenovirus virions were produced by Jinsirui Biotechnology (Nanjing, China). MCF-7 cells were transduced with lent-MnSOD virions at a multiplicity of infection (MOI) of 10. The transduced cells were treated with 4 µg/ml puromycin to induce stable MnSOD expressing Lent-MnSOD MCF-7 cells. Furthermore, MCF-7 cells were infected with Ad-sh-MnSOD or control Ad-sh at a MOI of 10 and treated with 2 µg/ml puromycin to generate stable MnSOD silencing Ad-sh-MnSOD MCF-7 cells. The efficiency of MnSOD overexpression or silencing was examined by Western blot.

CCK-8 Assay

Wild-type MCF-7 cells (1 × 10⁴ cells/well) were cultured in 96-well plates and treated in triplicate with 10% control mouse serum or 10% LD, MD, or HD QRYLD-supplemented serum, together with Lent-MnSOD and Ad-sh-MnSOD MCF-7 cells in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) for 24, 48 and 72 h. During the last 4 h culture, individual wells of cells were added with 10 μL of CCK-8 solution (Beyotime, Shanghai, China), and the viability of each group of cells was measured for the absorbance at 450 nm using a microplate reader.

Transcriptomic Analysis

MCF-7 cells were treated in triplicate with control mouse serum as the control or MD QRYLD-supplemented serum for 48 h. Their total RNA was extracted using TRIzol (Thermo Fisher Scientific, Waltham, MA, USA), and their mRNAs were sorted using an Oligotex mRNA sorting kit (Qiagen, Hilden, Germany) per the manufacturer's instructions. After qualification and quantification of mRNA using the Illumina HiSeq™ 2000 system, the mRNA samples from each group were reverse-transcribed into cDNA to generate cDNA libraries using a SMART-Seq V4 kit (Takara, Kyoto, Japan). The cDNA libraries were sequenced in the NovaSeq 6000 system (Illumina, San Diego, CA, USA). The differentially expressed genes (DEGs) were identified by a P-value of <.05 or a fold change of >|2.0|. The biological nature of DEGs was analyzed using DAVID Bioinformatics Resources 6.7, and their biological processes or signaling pathways were analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The transcriptomic analysis was conducted by MED-X institute, the First Affiliated Hospital of Medical School of Xi’an Jiaotong University.

Transwell Invasion Assay

MCF-7 cells (4 × 10⁴ cells/well) were treated with control mouse serum or MD QRYLD-supplemented serum for 48 h. The cells, together with the same number of Ad-sh-MnSOD MCF-7 or Lent-MnSOD MCF-7 cells, were cultured into the upper chamber, which had been coated with Matrigel (Thermo Fisher Scientific), and the bottom chamber was filled with 10% FBS-containing medium. After 24-h culture, the cells on the upper chamber surface membrane were removed, and the invaded cells on the upper chamber bottom surface were fixed in 4.0% paraformaldehyde and stained with 0.1% crystal violet solution for 10 min, followed by photoimaging under a Leica DMil inverted microscope (Leica, Wetzlar, Germany). The number of invaded cells was counted in a blinded manner.

Wound-Healing Assay

MCF-7 cells were treated with control mouse serum or MD QRYLD-supplemented serum for 48 h. The cells, together with the same number of Ad-sh-MnSOD MCF-7 or Lent-MnSOD MCF-7 cells (1 × 10⁶ cells/well), were cultured in six-well plates. When the cells reached 95% confluency, the monolayer cells were wounded using a 10-μL sterile pipette tip. The wounded areas were photographed immediately after scratch and after 48 h of culture. The wound-healing ability of each group of cells was analyzed using ImageJ software (US National Institutes of Health, Bethesda, MD, USA).

Apoptosis Detection by Flow Cytometry

Ad-sh-MnSOD MCF-7, Lent-MnSOD MCF-7, and wild-type MCF-7 cells were treated in triplicate with control mouse serum or MD QRYLD-supplemented serum for 48 h, harvested, and stained with Annexin V–fluorescein isothiocyanate (Solarbio) and propidium iodide (Solarbio) for 10 min in the dark. The percentage of apoptotic cells was analyzed by flow cytometry, and the data were analyzed using FlowJo software (Becton, Dickenson, Franklin Lakes, NJ, USA).

Western Blot

Ad-sh-MnSOD MCF-7, Lent-MnSOD MCF-7, and MCF-7 cells were treated with control serum or MD QRYLD-supplemented serum for 48 h, harvested, and lysed in lysis buffer, followed by centrifugation. After measuring protein concentrations using a BCA kit, the cell lysates (30 µg/lane) were resolved by sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 10% gels and transferred onto polyvinylidene difluoride membranes. After being blocked with 5% skimmed dry milk powder in TBST for 2 h, the membranes were probed with primary antibodies against MnSOD, CaMKII, AMPK, HIF-1α, Glut-1, c-Myc, hexokinase 2 (HK-2), phosphofructokinase 1 (PFK-1), lactate dehydrogenase A (LDH-A), pyruvate kinase isozyme 2 (PKM-2), and β-actin (1:1000, all from Abiowell Biotechnology, Changsha, China) at 4°C overnight, The bound antibody was reacted with horseradish peroxidase-conjugated secondary antibodies (Abiowell Biotechnology), followed by visualizing with enhanced chemiluminescence reagents. The data were analyzed by densitometric scanning using ImageJ.

Glucose Uptake and Lactate Levels

MCF-7 cells were treated with control mouse serum or MD QRYLD-supplemented serum for 48 h. The impact of QRYLD treatment on glucose uptake in those cells, together with the same number of Ad-sh-MnSOD MCF-7 or Lent-MnSOD MCF-7 cells was tested using a 2-deoxyglucose (2-DG)–based colorimetric glucose uptake assay kit (Abcam, Cambridge, UK) per the manufacturer's protocol. Briefly, the cells were glucose-starved for 40 min, stimulated with insulin for 20 min, and exposed to 1 mM 2-DG for 20 min, followed by washing. The cells were lysed, and heated at 80 °C for 40 min. After neutralization, the samples were incubated with the reaction mixture at 37 °C for 30 min, neutralized, and incubated with reaction B (Lactate oxidase and Horseradish peroxidase). The levels of 2-DG6P–related NADPH in each group of samples were measured for the absorbance at 412 nm in a microplate reader. The concentrations of accumulated glucose were calculated according to the standard curve established using standard 2-DG6P provided by the manufacturer. In addition, the levels of lactic acid in the supernatants of cultured cells were measured in a fully automated biochemical analyzer (Solarbio).

Animal Studies

Female BALB/c nude mice were obtained from the Laboratory Animal Center, Xi’an Jiaotong University Health Science Center and housed in a specific pathogen-free facility in our university. The mice were randomized, and implanted with 3 × 10⁶ MCF-7, Ad-sh-MnSOD MCF-7, or Lent-MnSOD MCF-7 cells in 100 µl of saline into their breast fat pads. Some mice were intravenously administered 11.375 g kg⁻¹ day⁻¹ QRYLD in 0.3 ml of saline daily beginning on day 5 post-inoculation for 10 consecutive days. Other groups of mice received the same volume of saline (n = 6 per group). The volumes of implanted tumors and body weights of mice were measured every other day for 4 weeks. At the end of the experiment, the mice were euthanized, and their tumor tissues were dissected, imaged, and weighed. The tumor tissues were fixed in 10% formalin and embedded in paraffin. The tumor tissue sections (4 µm) were subjected to immunohistochemistry using primary antibodies against MnSOD (1:100), CaMKII (1:200), and AMPK (1:2000, all from Abiowell Biotechnology); counterstained with hematoxylin; and analyzed using ImageJ software. All animal experiments were performed strictly following applicable national and institutional guidelines and approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University (No. 2017 lunshenkezi No. 44, dated March 2, 2017).

Statistical Analysis

Data are presented as the mean ± SEM. The difference among three or more groups was analyzed by one-way ANOVA and post hoc Tukey's test. The comparison between groups was performed using Student's t-test. All statistical analyses were conducted using GraphPad Prism 8 software (GraphPad Software, Boston, MA, USA). Statistical significance was defined when a P-value of < .05.

Results

QRYLD Aqueous Extracts Contain Several Bioactive Components

To understand the biological functions of QRYLD, we prepared the aqueous extracts of QRYLD using 3300 g QRYLD and obtained 410 g QRYLD dry powder, leading to a powder recovery rate of approximately 12.4%. HPLC analyses revealed six main chemical compounds at high concentrations in QRYLD (Figure 1), namely chlorogenic acid (133.21 ± 19.05 mg/g), caffeic acid (151.22 ± 11.38 mg/g), quercetin (125 ± 2.96 mg/g), rutin (145.11 ± 16.29 mg/g), ferulic acid (179.53 ± 23.58 mg/g), and luteolin (102.39 ± 8.23 mg/g). Hence, the QRYLD aqueous extracts contained several chemical compounds with high bioactivity, and their interactions might contribute to the functions of QRYLD.

Figure 1.

HPLC Analysis of the Chemical Components in QRYLD Aqueous Extracts. (A) Drug Standards. (B) QRYLD Aqueous Extracts. 1, Chlorogenic Acid; 2, Caffeic Acid; 3, Quercetin; 4, Rutin; 5, Ferulic Acid; 6, Luteolin.

QRYLD Targets Several Biological Processes and Signaling Pathways in Breast Cancer Cells

Next, we explored whether QRYLD treatment could modulate the transcriptome in MCF-7 cells. Following treatment of MCF-7 cells with control mouse serum or QRYLD-supplemented serum for 48 h, the transcriptomes of control and QRYLD-treated MCF-7 cells were analyzed by RNA sequencing. Compared with the control serum-treated MCF-7 cells, treatment with QRYLD-supplemented serum caused 2918 DEGs, including 1693 upregulated and 1225 downregulated genes, in the QRYLD-treated cells. Notably, 293 of these DEGs, including 133 downregulated and 160 upregulated DEGs, were oncogenes and tumor suppressor genes (Figure 2A). Bioinformatic analyses predicted that these 293 DEGs were mainly involved in metabolism-related signaling pathways or biological processes. GO and KEGG analyses unveiled that the top 50 DEGs were directly related to the Warburg effect (Figure 2B). The connections among these targets and signal pathways predicted that these 293 DEGs were mainly involved in response to oxidative stress, cancer-related signaling pathways, glycogen synthesis and metabolism, the pentose phosphate pathway, the TCA cycle, glucose metabolism regulation, gluconeogenesis, glycolysis, and the MnSOD/MAPK signaling (Figure 2C). Possibly, QRYLD may target MnSOD in breast cancer.

Figure 2.

Bioinformatic Analysis of the Transcriptomes of QRYLD-Treated MCF-7 Cells. (A) Heatmap Analysis of DEGs. 1–3, the Control MCF-7 Cells; 4–6, the QRYLD-Treated MCF-7 Cells. (B) PPI Analysis among the Targets of QRYLD. (C) Enrichment Analysis of DEGs.

QRYLD Treatment Limits the Malignant Behaviors of MCF-7 Cells

To understand the importance of MnSOD in the malignant behaviors of breast cancer cells, we generated stable MnSOD-silenced Ad-sh-MnSOD cells and MnSOD-overexpressing Lent-MnSOD MCF-7 cells. Subsequently, wild-type MCF-7 cells were treated with control serum or LD, MD, or HD QRYLD-supplemented serum, and their proliferation was tested by the CCK-8 assay. Compared with the proliferation in the control group, the proliferation of Ad-sh-MnSOD MCF-7 cells was significantly reduced (P < .01), whereas that of Lent-MnSOD MCF-7 cells was significantly enhanced (P < .01). In addition, the proliferation of QRYLD-treated MCF-7 cells (LD, MD, or HD) was significantly reduced (P < .05, Figure 3A). Notably, treatment with MD QRYLD-medicated serum for 48 h inhibited cell proliferation by 50%. Accordingly, we used MD QRYLD-supplemented serum for the subsequent in vitro experiments. Transwell invasion assays indicated that the number of invaded cells was significantly lower in the QRYLD group than in the control and Lent-MnSOD groups, whereas it was slightly greater than that in in the Ad-sh-MnSOD group (Figure 3B). A similar pattern of wound healing was observed among the different groups of cells (Figure 3C).

Figure 3.

QRYLD Treatment, Similar to MnSOD Silencing, Supresses the Malignancy of MCF-7 Cells in vitro. (A) the Effect of QRYLD on Cell Viability. MCF-7 Cells Were Treated with Control serum or the Indicated Concentrations of QRYLD-Supplemented serum and Tested Together with Ad-sh-MnSOD and Lent-MnSOD MCF-7 Cells in Triplicate to Assess Their Viability by the CCK-8 Assay at the Indicated Time Points. (B) the Effects of QRYLD on Cell Invasion. (C) the Effects of QRYLD on Wound Healing in MCF-7 Cells. (D) Flow Cytometry Analysis of the Effects of QRYLD on Cell Apoptosis. Scale bar, 50 μm. Data are Presented as the Mean ± SEM of Each Group from Three Separate Experiments, *P < .05, **P < .01 Versus the Control.

Flow cytometry revealed that compared with the control MCF-7 cells, QRYLD treatment significantly increased the percentages of apoptotic MCF-7 cells (P < .05) and MnSOD silencing also further increased the eprcentages of apoptotic MCF-7 cells (P < .01, Figure 3D). In contrast, MnSOD overexpression significantly reduced the percentages of spontaneously apoptotic MCF-7 cells (P < .05). Collectively, the reduced cell proliferation, invasion and wound healing, together with enhanced apoptosis, indicated that QRYLD treatment, similar to MnSOD silencing, limited the malignant behaviors of MCF-7 cells in vitro.

QRYLD Treatment Inhibits Glucose Uptake and Lactic Acid Production and Reduces the Warburg Effect in MCF-7 Cells by Attenuating the MnSOD/CaMKII/AMPK Signaling

To further understand the pharmacological action of QRYLD, we tested its effects on glucose uptake and lactic acid production in MCF-7 cells. Following treatment with MD QRYLD-supplemented serum for 48 h, the levels of glucose uptake in the different groups of MCF-7 cells were measured by 2-DG–based colorimetric assays. Compared with the control MCF-7 cells, the levels of glucose uptake and lactic acid production were significantly lower in the QRYLD-treated MCF-7 and Ad-sh-MnSOD MCF-7 cells while they were significantly higher in the Lent-MnSOD MCF-7 cells (P < .05 or P < .01, Figure 4A). Apparently, treatment with QRYLD, like MnSOD silencing, decreased glucose uptake and lactic acid production to suppress the Warburg effect in MCF-7 cells.

Figure 4.

QRYLD Treatment, Similar to MnSOD Silencing, Modulates the Warburg Effect in MCF-7 Cells. (A) the Effect of QRYLD on Glucose Uptake and Lactic Acid Production. (B) the Expression of key Regulatory Factors in the Warburg Effect. (C) the Expression of Metabolic Enzymes Involved in the Warburg Effect. (D) the Expression of MnSOD/CaMKII/AMPK Pathway Proteins in the Warburg Effect. Data are Presented as the Mean ± SEM of Each Group of Cells from Three Separate Experiments, *P < .05, **P < .01 Versus the Control.

It is well known that several regulators are crucial for the Warburg effect in cancers. To explore the molecular mechanism by which QRYLD treatment suppressed the Warburg effect in MCF-7 cells, we tested the relative levels of HIF-1α, Glut-1, and C-Myc expression in the different groups of cells by Western blot. Indead, the relative levels of HIF-1α, Glut-1, and C-Myc were significantly lower in the QRYLD-treated MCF-7 cells than in the control and Lent-MnSOD MCF-7 cells but higher than that in the Ad-sh-MnSOD MCF-7 cells (Figure 4B). Similar results were observed in the relative levels of HK-2, PFK-1, LDH-A, and PKM-2 expression in the different groups of MCF-7 cells (Figure 4C). These data indicated that QRYLD, similar to MnSOD silencing, inhibited the expression of these regulators and metabolic enzymes, leading to its inhibition on the Warburg effect in MCF-7 cells.

Given the importance of MnSOD in the pharmacological functions of QRYLD, we tested whether QRYLD treatment could modulate the MnSOD/CaMKII/AMPK signaling in MCF-7 cells by Western blot. As expected, the relative levels of MnSOD expression were significantly lower in the QRYLD-treated MCF-7 cells than that in the control and Lent-MnSOD MCF-7 cells, but significantly higher than that in the Ad-sh-MnSOD MCF-7 cells (Figure 4D). These data demonstrated the efficiency of MnSOD overexpression and silencing in MCF-7 cells and suggest that QRYLD may target MnSOD expression in MCF-7 cells. A similar pattern of CaMKII and AMPK expression was observed in the different groups of MCF-7 cells. Collectively, these data provided novel evidence to demonstrate that QRYLD, similar to MnSOD silencing, inhibited glucose uptake and lactic acid production, reducing the Warburg effect in MCF-7 cells by suppressing the expression of several regulators and metabolic enzymes and attenuating the MnSOD/CaMKII/AMPK signaling.

QRYLD Treatment Inhibits the Growth of Breast Cancers in Mice

Finally, we tested the therapeutic effect of QRYLD on the growth of xenografted breast cancers in mice. After establishment of wild-type, Ad-sh-MnSOD, or Lent-MnSOD MCF-7 xenograft tumors, the wild-type tumor-bearing mice were randomized and treated intravenously with vehicle saline or MD QRYLD daily from day 5 to day 15. The dynamic growth of implanted tumors in the different groups of mice was monitored. Compared with the control group, QRYLD treatment, similar to MnSOD silencing, significantly decreased tumor volumes and weights in mice, whereas induction of MnSOD overexpression significantly increased tumor volumes and weights in mice (Figure 5A and C). Conversely, there was no significant difference in body weights among the different groups of mice (Figure 5B). Immunohistochemistry illustrated that compared with the control tumors, the tumors from QRYLD-treated mice, similar to that from the Ad-sh-MnSOD mice, exhibited a reduced level of MnSOD, CaMKII, and AMPK expression, whereas their expression was significantly up-regulated in the Lent-MnSOD tumors (Figure 5D). Together, these data indicated that MnSOD overexpression significantly enhanced the MnSOD/CaMKII/AMPK signaling to promote the growth of implanted MCF-7 tumors in mice and QRYLD treatment, similar to MnSOD silencing significantly inhibited the growth of implanted breast tumors in mice by attenuating the MnSOD/CaMKII/AMPK signaling.

Figure 5.

QRYLD Treatment Suppresses the Tumor Growth in Mice. (A) Tumor Volumes Were Measured in Mice Every Other day for 4 Consecutive Weeks. (B) the Body Weights of Mice Were Measured Every Other day for 4 Consecutive Weeks. (C) Images of all Dissected Tumors and Their Weights. (D) Immunohistochemistry Analyses of MnSOD, CaMKII, and AMPK Expression in Tumor Tissues from Each Group of Mice (n = 6 per Group). Scale bar, 50 μm. Data are Presented as the Mean ±SEM of Each Group of Mice from Three Separate Experiments, *P < .05, **P < .01 Versus the Control.

Discussion

This study explored whether and how QRYLD treatment modulated the malignant behaviors of MCF-7 cells. First, we identified bioactive compounds in the QRYLD aqueous extracts by HPLC and they mainly included high concentrations of chlorogenic acid, caffeic acid, quercetin, rutin, ferulic acid, and luteolin. The synergistic and addictive effects of these bioactive compounds may contributed to their biological functions. Biological analyses indicated that QRYLD attenuated the MnSOD/CaMKII/AMPK signaling to inhibit the Warburg effect and malignant behavior in MCF-7 cells. Evidently, transcriptomic analysis indicated that QRYLD treatment modulated the expression of several genes, such as MnSOD, in MCF-7 cells. Bioinformatic analysis unveiled that the DEGs mainly participated in metabolism-related signaling pathways, such as the MnSOD/MAPK signaling pathway, and biological processes, including the Warburg effect. Furthermore, QRYLD treatment significantly inhibited the malignant behaviors of MCF-7 cells by inhibiting their proliferation, migration, invasion, spontaneous apoptosis in vitro and tumor growth in vivo. In addition, QRYLD treatment decreased the expression of MnSOD, CaMKII, and AMPK in MCF-7 cells and in the implanted tumors in mice. Interestingly, the therapeutic effects of QRYLD treatment were less than that of MnSOD silencing in MCF-7 cells. These data support the notion that QRYLD may suppress MnSOD expression and attenuate the MnSOD/CaMKII/AMPK signaling to inhibit the Warburg effect and malignant behaviors in MCF-7 cells. Our novel findings suggest that QRYLD may target MnSOD expression and may provide new pharmacological mechanisms by which QRYLD treatment inhibits the malignancy of breast cancer (Figure 6).

Figure 6.

A Diagram Illustrates the Molecular Mechanisms by Which QRYLD Treatment Attenuates the MnSOD/CaMKII/AMPK Signaling and Warburg Effect in Breast Cancer.

MnSOD expression is usually upregulated in cancer cells, and MnSOD can promote the release of H₂O₂ in mitochondria and upregulate the expression of CaMKII, which can phosphorylate and activate AMPK. AMPK is an important energy receptor in cells that can enhance glycolysis and the Warburg effect.^42–46 AMPK activation is also crucial for cellular responses to stress, autophagy, survival, and cancer cell growth.^47–51 By markedly scavenging mitochondrial superoxide, MnSOD overexpression reshapes the ROS landscape, modifying its composition and spatial dynamics. Consequently, the outcome transcends a mere decrease in ROS, constituting a fundamental reprogramming of the cellular redox status.^52,53 This reprogramming activates transcription factors sensitive to oxidative changes, such as HIF-1α, ultimately promoting the activation of a genetic program that enhances proliferation, migration, invasion, and glycolysis. Accordingly, MnSOD is a potent antioxidant and an oncogenic factor that supports the survival of cells under hypoxic conditions. MnSOD can shift glucose metabolism from oxidative phosphorylation to glycolysis in human triple-negative breast cancer cells by transmitting the glucose signal and changing the oxygen transmission pathway.^54,55 Consistently, we found that MnSOD overexpression enhanced glycolysis in MCF-7 cells by increasing CaMKII and AMPK expression and promoted malignant behaviors, such as proliferation, migration, wound healing, and invasion, in MCF-7 cells.⁵⁶ Conversely, treatment with QRYLD to reduce MNSOD expression or MnSOD silencing dramatically decreased glucose uptake, lactic acid production, and Glut-1 expression, which are hallmarks of suppressed glycolysis, extending previous findings.^57,58

Our data disagreed with a previous observation that MnSOD deficiency does not significantly alter the levels of glycolysis in breast cancer cells. The difference between these findings may stem from the use of different breast cancer cell lines with varying metabolic states. In fact, MnSOD silencing promoted the occurrence of oxidative phosphorylation.⁵⁹ In breast cancer cells, MnSOD may maintain a stable increase in H₂O₂ levels, thus maintaining the activation of AMPK and the transformation of intracellular metabolism into glycolysis, whereas MnSOD silencing or AMPK inhibition can reduce the growth of cells.⁶⁰ Hence, the MnSOD/CaMKII/AMPK axis may be crucial for supporting the bioenergetics of cancer cells, and it can promote the progression of breast cancer.⁶¹

In our experiment, treatment with QRYLD or induction of MnSOD silencing down-regulated CaMKII and AMPK expression in MCF-7 cells. Furthermore, QRYLD treatment or MnSOD silencing significantly reduced the expression of HK-2, PFK-1, LDH-A, and PKM-2, the key metabolic enzymes in the Warburg effect in MCF-7 cells. Consequently, QRYLD treatment or MnSOD-silencing suppressed the malignant behaviors of MCF-7 cells in vitro and in vivo. By contrast, MnSOD overexpression significantly enhanced the expression of CaMKII, AMPK, which are key metabolic enzymes and critical regulators of proteins such as HIF-1α, Glut-1, and c-Myc expression, in MCF7 cells, and these changes were accompanied by enhanced malignant behaviors of MCF-7 cells in vitro and in vivo. These parallel data suggest that the MnSOD/CaMKII/AMPK axis may be a key factor regulating the progression of breast cancer, and this axis may represent a therapeutic target for breast cancer treatment.

In conclusion, our data indicated that QRYLD contained several bioactive components. However, we did not validate which compound(s) and their interactions are responsible for the biological functions of QRYLD treatment in MCF-7 cells. We are interested in further investigating how these bioactive compounds contribute to the biological functions of QRYLD treatment in MCF-7 cells in the future. More importantly, we found that treatment with QRYLD significantly modulated the expression of many genes, including the metabolism-related gene MnSOD. QRYLD treatment, similarly as MnSOD silencing, significantly suppressed malignant behaviors and the Warburg effect of MCF-7 cells as well as tumor growth in vivo. These effects were associated with inhibition of the MnSOD/CaMKII/AMPK signaling in MCF-7 cells. Our findings may provide new insights into the pharmacological actions of QRYLD in inhibiting breast cancer growth and unveil new therapeutic targets for designing therapies for breast cancer.

Abbreviations

QRYLD

Qing-Re-Yi-Liu decoction

MnSOD

Manganese superoxide dismutase

CaMKII

Calmodulin-dependent kinase II

AMPK

AMP-activated protein kinase

Glut-1

Glucose transporter-1

HIF-1α

Hypoxia-inducible factor 1α

HK-2

Hexokinase-2

PFK-1

Phosphofructokinase 1

LDH-A

Lactate dehydrogenase A

PKM-2

Pyruvate kinase isozyme 2

MOI

Multiplicity of infection

DEGs

Differentially expressed genes

PPIs

Protein–proteininteractions

Footnotes

ORCID iD

Zhe Zhang

Ethics Approval and Consent to Participate

All experiments were performed following the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH Publication No. 85-23, revised 1996). The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University (No. 2017 lunshenkezi No. 44, dated March 2, 2017).

Author Contributions

Yuan Cao performed statistical analysis. Lianqing Sun provided the plant materials. Junxia Wang performed phytochemical analysis. Jing Du performed the in vivo and in vitro experiments. Ying Zhang and Ying Yuan conceived and supervised the study. Zhe Zhang drafted the manuscript.

All authors read and approved the final manuscript.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by grants from the National Natural Science Foundation of China (no. 81703899), Shaanxi Provincial Natural Science Basic Research Program (no.2017JM8068), Shaanxi Provincial Administration of Traditional Chinese Medicine Project (no.15-JC021), Xi'an Jiaotong University First Affiliated Hospital General Project (no. 2021ZXY-06), The second batch of provincial-level Chinese medicine young and middle-aged scientific and technological backbone projects (no. 2023-ZQNY-008). Shaanxi province traditional Chinese medicine research and innovation team (TZKN-CXTD-07).

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of Data and Materials

The data included in this manuscript are available from the corresponding author.

References

Luo

, et al. Mechanistic role of Scutellaria baicalensis georgi in breast cancer therapy. Am J Chin Med. 2023;51(2):279–308.

Laiso

Ferreira

Rici

, et al. Cytotoxic effect of andrographis paniculata associated with 2-aminoethyl dihydrogen phosphate in triple-negative breast cells. Curr Issues Mol Biol. 2024;46(1):527–541.

Wang

Liu

, et al. Total alkaloids of Coptidis rhizoma combined with exercise inhibits tumor growth of orthotopically transplanted 4T1 breast cancer mice by blocking cell cycle G_1/S transformation. Chin J Chin Med. 2019;44(8):1635–1641.

Liu

Tang

Zhou

, et al. Bi-directional solid fermentation products of trametes robiniophila murr with Radix isatidis inhibit proliferation and metastasis of breast cancer cells. J Chin Med Assoc. 2018;81(6):520–530.

Zou

Hao

, et al. Pulsatilla saponinA affects proliferation and radiosensitivity of breast cancer cells by regulating miR-24-3p/RNF2 expression. Chin J Path. 2020;49(8):865–870.

Shuang

Wei

Xia

, et al. MnSOD is a metastatic suppressor through a novel redox-mediated regulation of the Warburg effect. Redox Biol. 2023;67(1):102897.

Kim

, et al. Loganic acid regulates the transition between epithelial and mesenchymal-like phenotypes by alleviating MnSOD expression in hepatocellular carcinoma cells. Life Sci. 2023;317(1):1–12.

Valentino

. The structure-function relationships and physiological roles of MnSOD mutants. Bios Rep. 2022;42(5):1–12. doi:10.1042/BSR20220202

Al Haq

Tseng

Chen

, et al. Targeting prooxidant MnSOD effect inhibits triple-negative breast cancer (TNBC) progression and M2 macrophage functions under the oncogenic stress. Cell Death Dis. 2022;13(1):1–15.

10.

Liu

, et al. Combined oncolytic adenovirus carrying MnSOD and mK5 genes both regulated by survivin promoter has a synergistic inhibitory effect on gastric cancer. Neoplasma. 2022;69(1):36–48.

11.

Gius

. Lysine 68 acetylation directs MnSOD as a tetrameric detoxification complex versus a monomeric tumor promoter. Clin Cancer Res. 2021;27(14):3862–3870.

12.

Sun

. Evaluation of toxicity, bacteriostatic, analgesic, anti-inflammatory, and antipyretic activities of Huangqin-Honghua-Pugongying-Jinyinhua extract. Vet Sci. 2021;8(10):1–12.

13.

Min

Xiao

Huaping

. Dandelion (Taraxacum genus): A review of chemical constituents and pharmacological effects. Mol. 2023;28(13):1–31.

14.

Zhang

, et al. Updates and advances on pharmacological properties of Taraxacum mongolicum Hand.-Mazz and its potential applications. Food Chem. 2022;373(1):131–143.

15.

Mehdi

Thomas

Karl

, et al. Ethnobotany of the genus Taraxacum—phytochemicals and antimicrobial activity. Phy Res. 2018;32(11):2131–2145.

16.

Wang

Tang

Sun

, et al. Effects of Iphigenia indica extract on proliferation and apoptosis of human colorectal cancer cell line SW480. Chin J Basic Med. 2021;39(12):1754–1758.

17.

Song

Guo

Wang

, et al. Targeting the phosphatidylinositol 3-kinase/AKT1 signaling pathway: Iphigenia indica extracts induce apoptosis in lung adenocarcinoma cells. Sci Adv Mater. 2023;15(4):571–578.

18.

Tao

Zhao

Qian

, et al. The complete chloroplast genome sequence of the medicinal plant Iphigenia indica kunth (Liliaceae). Mitochondrial DNA B Resour. 2020;5(2):1545–1547.

19.

Jun

Liyao

Zhen

, et al. Antibacterial potential of Forsythia suspensa polysaccharide against resistant enterobacter cloacae with SHV-12 extended-spectrum β-lactamase. J Cell Mol Med. 2020;24(15):8763–8771.

20.

Zhao

Dai

, et al. Alkaloids bearing rare skeletons from Forsythia suspensa with anti-inflammatory and anti-viral activities in vitro. Phytochem. 2021;186(1):1–12.

21.

Shao

Zhang

Yang

, et al. Neuroprotective and anti-inflammatory phenylethanoid glycosides from the fruits of Forsythia suspense. Bioorg Chem. 2021;113(1):1–15.

22.

Sun

Zhao

, et al. New C-9-monoterpenoid alkaloids featuring a rare skeleton with anti-inflammatory and antiviral activities from Forsythia suspense. Chem Biodivers. 2022;19(8):1–7.

23.

Wang

Xia

, et al. Combining network pharmacology with chromatographic fingerprinting and multicomponent quantitative analysis for the quality evaluation of Moutan cortex. Bio Chr. 2022;36(10):1–12.

24.

Yang

Liu

, et al. Insight into seasonal change of phytochemicals, antioxidant, and anti-aging activities of root bark of Paeonia suffruticosa (Cortex moutan) combined with multivariate statistical analysis. Mol. 2021;26(20):1–19.

25.

Zhang

Wang

, et al. Grey relational analysis combined with network pharmacology to identify antioxidant components and uncover its mechanism from Moutan cortex. Front Pharmacol. 2021;12(1):1–14.

26.

Zhou

Lin

Meng

. Discrimination and chemical composition quantitative model of raw Moutan cortex and Moutan cortex carbon based on electronic nose. Math Biosci Eng. 2022;19(9):9079–9097.

27.

Yin

You

. Molecular mechanism of anti-colorectal cancer effect of Hedyotis diffusa willd and its extracts. Front Pharmacol. 2022;13(1):1–10.

28.

. Effect of Hedyotis diffusa polysaccharide on apoptosis of thyroid cancer cells. Pak J Zool. 2022;54(5):1803–1810.

29.

Dong

Zhang

. Hedyotis diffusa willd extract protects rat renal tubular epithelial cells from high glucose-induced injury by inhibiting PI3K/AKT signaling pathway. Scie. 2022;105(3):532–537.

30.

, et al. The anti-inflammatory effects of Hedyotis diffusa willd on SLE with STAT3 as a key target. J Ethnopharmacol. 2022;298(1):1–14.

31.

Yang

Hao

, et al. Research progress on chemical constituents and pharmacological activities of iridoid glycosides in Lonicera japonica. Chin J Chin. 2021;46(11):2746–2752.

32.

Jiang

Chen

Jiang

, et al. Luteolin in Lonicera japonica inhibits the proliferation of white spot syndrome virus in the crayfish procambarus clarkia. Aquaculture. 2022;550(1):1–10.

33.

Chen

, et al. Lonicera japonica thunb as a promising antibacterial agent for bacillus cereus ATCC14579 based on network pharmacology, metabolomics, and in vitro experiments. Rsc Adv. 2023;13(21):15379–15390.

34.

Yang

, et al. Extraction, purification, structural characteristics, health benefits, and application of the polysaccharides from Lonicera japonica thumb. A Rev Mol. 2023;28(12):1–11.

35.

Dar

Senthilmurugan

Venkatesan

. Antibacterial, antioxidant potential and functional group analysis of kashmir grown Prunella vulgaris L. root extract. Int J Bot Stu. 2022;7(5):19–25.

36.

Bai

Wang

, et al. Network pharmacology analysis, molecular docking, and in vitro verification reveal the action mechanism of Prunella vulgaris L. in treating breast vancer. Evid-Based Compl Alt. 2022;12(1):1–19.

37.

Dar

Senthilmurugan

Ali

, et al. Studies on the isolation and identification of the antibacterial compound from Prunella vulgaris L. flower extract. J King Saud Univ Sci. 2022;34(8):1–6.

38.

Kim

Lee

Hwang

, et al. Anti-osteoarthritic effects of Prunella Vulgaris and Gentiana lutea in vitro and in vivo. Antioxidants. 2023;12(1):47–57.

39.

Liang

Duan

Zhou

, et al. Three new cyclopeptides from the Lycii cortex. Fitoterapia. 2025;185(1):1–10.

40.

Guo

Yin

, et al. Study on the mechanism of Cortex Lycii on lung cancer based on network pharmacology combined with experimental validation. J Ethno. 2022;293(1):1–10.

41.

Zhao

Yuan

Zhu

, et al. Mechanism of hypolipidemic effect of Lycii cortex based on network pharmacology and molecular docking. Chin Trad Drugs. 2023;54(5):1487–1497.

42.

Quiros

Gonzalez

Alcon

, et al. Androgen-dependent prostate cancer cells reprogram their metabolic signature upon glut-1 upregulation by manganese superoxide dismutase. Free Radi Bio Med. 2021;165(1):1–12.

43.

Gao

Zhu

Tran

, et al. MnSOD lysine 68 acetylation leads to cisplatin and doxorubicin resistance due to aberrant mitochondrial metabolism. Int J Biol Sci. 2021;17(5):1203–1216.

44.

Cao

Liu

, et al. Genistein inhibits lung cancer cell stem-like characteristics by modulating MnSOD and FoxM1 expression. Oncol Lett. 2020;20(3):2506–2515.

45.

Torrens

Cordani

Mullappilly

, et al. Mutant p53 induces SIRT3/MnSOD axis to moderate ROS production in melanoma cells. Arch Bio Bio. 2020;679(2):1–10.

46.

Sun

Liu

, et al. ACT001 Modulates the NF-kappa B/MnSOD/ROS axis by targeting IKK beta to inhibit glioblastoma cell growth. J Mol Med. 2020;98(2):263–277.

47.

Perera

Martinez

AKF

Storz

. MnSOD mimetic mitoquinone mesylate (MitoQ) increases DCLK1+pancreatic cancer stem cells. Cancer Res. 2023;83(7):4775–4779.

48.

Zhu

Zou

Dean

, et al. Lysine 68 acetylation directs MnSOD as a tetrameric detoxification complex versus a monomeric tumor promoter. Nat Commun. 2019;10(1):1–15.

49.

Fan

Hsu

Hung

, et al. Reduction in MnSOD promotes the migration and invasion of squamous carcinoma cells. Int J Oncol. 2019;54(5):1639–1650.

50.

Lim

, et al. MnSOD mediates shear stress-promoted tumor cell migration and adhesion. Free Radi Bio Med. 2018;129(1):46–58.

51.

Liu

Yuan

Cao

, et al. Isovitexin suppresses stemness of lung cancer stem-like cells through blockage of MnSOD/CaMKII/AMPK signaling and glycolysis inhibition. Biomed Res Int. 2021;21(1):1–15.

52.

Jetawattana

Venkataraman

Domann

, et al. A role for MnSOD and p53 in regulating HIF-1 alpha in breast cancer cell lines. Free Radi Bio Med. 2005;39(2):166–176.

53.

Jetawattana

Venkataraman

Teoh

MLT

, et al. Redox regulation of HIF-1 alpha by MnSOD via ROS. Free Radi Bio Med. 2006;41(1):110–119.

54.

Hart

Fricano

, et al. Mangenese superoxide dismutase (MnSOD) promotes stem-like cell phenotypes in breast cancer. Faseb J. 2017;31(3):809–815.

55.

Al Haq

Tseng

Chen

, et al. Targeting prooxidant MnSOD effect inhibits triple-negative breast cancer (TNBC) progression and M2 macrophage functions under the oncogenic stress. Cell Death Dis. 2022;13(1):1–15.

56.

Hart

Fricano

Minshall

, et al. Loss of caveolin-1 results in a MnSOD-dependent glycolytic shift in breast cancer. Free Radi Bio Med. 2012;53(1):43–53.

57.

Ambrosone

Choi

Barlow

, et al. Pharmacogenetics and breast cancer treatment outcomes: Results on oxidative stress related genotypes (MPO, MnSOD) from a southwest oncology group trial (S8897). Int J Biol Marker. 2007;22(1):61–69.

58.

Weydert

Zhang

Sun

, et al. Increased oxidative stress created by adenoviral MnSOD or CuZnSOD plus BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) inhibits breast cancer cell growth. Free Radi Bio Med. 2008;44(5):856–867.

59.

Quiros

Gonzalez

Alcon

, et al. Androgen-dependent prostate cancer cells reprogram their metabolic signature upon glut-1 upregulation by manganese superoxide dismutase (mnsod/SOD2). Free Radi Bio Med. 2021;165(1):97–107.

60.

Hart

Mao

Abreu

ALP

, et al. MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK-dependent signalling in cancer. Nat Commun. 2015;6(1):1–14.

61.

Ansenberger

Mao

Green

, et al. MnSOD regulation of AMPK-mediated transition to glycolysis in breast cancer. Free Radi Bio Med. 2012;53(S1):39–49.

Qing-Re-Yi-Liu Decoction Suppresses the Malignant Behaviors of Breast Cancer by Attenuating the MnSOD/CaMKII/AMPK Signaling and Warburg Effect

Abstract

Keywords

Introduction

Materials and Methods

QRYLD

Preparation of QRYLD-Supplemented Serum

Cell Culture

Transfection and Transduction

CCK-8 Assay

Transcriptomic Analysis

Transwell Invasion Assay

Wound-Healing Assay

Apoptosis Detection by Flow Cytometry

Western Blot

Glucose Uptake and Lactate Levels

Animal Studies

Statistical Analysis

Results

QRYLD Aqueous Extracts Contain Several Bioactive Components

QRYLD Targets Several Biological Processes and Signaling Pathways in Breast Cancer Cells

QRYLD Treatment Limits the Malignant Behaviors of MCF-7 Cells

QRYLD Treatment Inhibits Glucose Uptake and Lactic Acid Production and Reduces the Warburg Effect in MCF-7 Cells by Attenuating the MnSOD/CaMKII/AMPK Signaling

QRYLD Treatment Inhibits the Growth of Breast Cancers in Mice

Discussion

Abbreviations

Footnotes

ORCID iD

Ethics Approval and Consent to Participate

Author Contributions

Funding

Declaration of Conflicting Interests

Availability of Data and Materials

References